Janus Henderson Group PLC Has $189.48 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Janus Henderson Group PLC grew its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 4,581,642 shares of the company’s stock after buying an additional 101,358 shares during the period. Janus Henderson Group PLC owned approximately 9.54% of Mirum Pharmaceuticals worth $189,481,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in MIRM. Raymond James Financial Inc. acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $10,611,000. D. E. Shaw & Co. Inc. acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $6,507,000. Marshall Wace LLP raised its position in shares of Mirum Pharmaceuticals by 641.6% during the fourth quarter. Marshall Wace LLP now owns 175,913 shares of the company’s stock valued at $7,274,000 after buying an additional 152,191 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Mirum Pharmaceuticals by 10.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company’s stock valued at $58,831,000 after buying an additional 138,623 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Mirum Pharmaceuticals by 162.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company’s stock valued at $7,317,000 after buying an additional 109,585 shares during the last quarter.

Insider Activity

In related news, Director Patrick J. Heron purchased 1,335 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average cost of $45.57 per share, with a total value of $60,835.95. Following the completion of the purchase, the director now directly owns 163,643 shares of the company’s stock, valued at $7,457,211.51. This trade represents a 0.82% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Peter Radovich sold 7,879 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $348,330.59. Following the sale, the chief operating officer now directly owns 18,672 shares in the company, valued at $825,489.12. This trade represents a 29.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 92,764 shares of company stock valued at $4,109,161 over the last three months. 14.36% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on MIRM shares. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. JMP Securities increased their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a “market outperform” rating in a research report on Friday. Finally, HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $59.00.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $44.27 on Monday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -21.92 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.83 and a 1-year high of $54.23. The firm’s 50-day moving average price is $42.82 and its two-hundred day moving average price is $44.30.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $111.59 million for the quarter, compared to analysts’ expectations of $98.47 million. During the same period in the prior year, the firm earned ($0.54) earnings per share. Mirum Pharmaceuticals’s revenue was up 61.2% compared to the same quarter last year. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.